Sharp Edge Labs, Inc. completed the acquisition of EVP Capital Inc. on December 12, 2024, through a reverse takeover. Following this transaction, EVP Capital was renamed Sharp Therapeutics Corp. and is now listed as a Tier 2 Life Sciences Issuer on the TSX Venture Exchange (TSXV).

As part of the arrangement, each issued and outstanding common share of Sharp Edge was exchanged for common shares of the resulting issuer on the basis of 31.2194 resulting issuer shares for each Sharp Edge share. This exchange resulted in the issuance of 282,208,481 resulting issuer shares, with former Sharp Edge stockholders holding 273,663,281 of these shares. Additionally, shares were reserved for issuance to former holders of options and warrants from both companies.

The new management team of Sharp Therapeutics Corp. includes Scott Sneddon as Chief Executive Officer and Chief Science Officer, and Edward Jonasson as Chief Financial Officer. The Board of Directors comprises Scott Sneddon, William R. Newlin, John L. Brooks III, Dietrich Stephan, John Hathaway, and Lorne Sugarman.

Bennett Jones acted for Sharp Edge Labs with a team led by Marshall Eidinger (Securities and M&A) and includes Dominique Carli, Geoff Davis, Tatiana Henkenhaf, Jonathan Berg (Securities and M&A), James Morand (Tax), Joseph Blinick and Will Bortolin (Litigation).